To investigate effects of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSFI on lymphoid cells in vivo, w e monitored changes in absolute lymphocyte counts, plasma concentrations of soluble interleukin-2 receptor (slL-2R) and soluble cytotoxic/suppressor (sCD8) antigens, and phenotypic changes of surface membrane antigens of peripheral mononuclear cells from 14 patients with malignant lymphoma treated with rhGM-CSF. Eight of the 14 patients had relapsed or had refractory non-Hodgkin's lymphoma (NHL) and received rhGM-CSF after intensive chemotherapy with novantrone (NO) and high-dose Ara-C (AC) (NOAC) as salvage regimen. Six other patients with NHL or Hodgkin's disease (HD) were in complete remission and treated with rhGM-CSF t o enhance peripheral hematopoietic progenitor cell harvest for autografting. An increase in absolute lymphocyte count a t the zenith of leukocyte elevation and a drastic increase in concentration of slL-2R from a median of 565 U/mL t o INCE HUMAN recombinant hematopoietic growth S factors were made available for clinical trials, much enthusiasm and great expectations have been aroused among hematologists and oncologist^.'-^ Recombinant human granulocyte or granulocyte-macrophage colony-stimulating factors (rhG-or rhGM-CSF) could be used clinically to shorten the period of neutropenia after intensive chemotherapy or to enhance bone marrow or peripheral hematopoietic progenitor cell harvest for a~tografting.'-~ Though a number of studies have demonstrated the benefit of rhG-CSF or rhGM-CSF in ameliorating myelosuppression and reducing the risk of serious infections after cytostatic treatment?.'' the impact of CSF applications on remission rate, response duration, and survival in cancer patients is not yet known.
Similar to other cytokines, hematopoietic growth factors might have pleiotropic effects, stimulating proliferation of cells of lineages other than their nomenclature RhGM-CSF, for example, is supposed to promote the growth and differentiation of progenitors within the myeloid lineages but has been found to stimulate the in vitro clonal growth of human colon adenocarcinoma cell lines.I3 It has recently been shown that rhGM-CSF and interleukin-3 (IL-3) can independently sustain the growth of an undifferentiated T-lymphoblastic cell line. 15 In the murine system, several T lymphoma/leukemia cell lines have been found to express the receptor for GM-CSF, and murine GM-CSF can induce the proliferation of HT-2 cells.I6 In humans, rhGM-CSF alone had no effect on T-cellknriched preparations of peripheral blood from normal persons, but a drastic proliferation was induced when the lymphocytes were previously "driven" by low doses of IL-2.I4 This stimulation of lymphocytes might have implications for the use of GM-CSF in lymphoid malignancies.
Thus far, rhGM-CSF has been applied mainly to patients with leukopenia caused by chemotherapy or associated with diseases. Reliable determination of absolute lymphocyte 6,700 U/mL on rhGM-CSF infusion were found in all patients. There was also a moderate increase in sCD8 levels from a median of 277 U/mL t o 470 U/mL. Ten patients were available for serial studies of phenotypic changes in surface membrane antigens. A significant increase in CD25+ (IL-2R+) (P = .0020) and CD4+ ( P = .0137) lymphocytes was observed in all patients, but nosignificant change in CD3-t. CD8+, TCRG1 +.or CD19+ cells. Elevations in absolute lymphocyte counts or in concentrations of slL-2R or sCD8 were not observed in four other patients during recovery from intensive chemotherapy without rhGM-CSF support. Our results provide evidence that administration of rhGM-CSF might activate lymphocytes in vivo. The impact of this activation on the remission rate and duration, as well as survival in patients with NHL, warrants further investigation. 0 1990 by The American Society of Hematology.
counts during severe leukopenia is frequently not feasible. Recently, activated lymphocytes positive for surface IL-2R have been shown to secrete soluble IL-2R antigen in vitro.I7 Similarly, a soluble form of CD8 has been found in the supernatant fluids of CD8 + leukemic cell lines and activated CD8+ lymphocytes.'' It has been suggested that measurements of released sIL-2R and suppressor-cytotoxic (sCD8) antigens may serve as an index of activated lymphocytes (CD25 + or IL2R+) and suppressor/cytotoxic (CD8+) cells. In patients with acute Epstein-Barr virus infection, elevation of sCD8 was observed and the serum levels correlated with the percentage of CD8 + /HLA-DR+ (activated CD8 +) T cells."
To investigate the effects of rhGM-CSF on lymphocytes in vivo, we monitored changes in absolute lymphocyte count, plasma concentrations of soluble IL-2 receptor (sIL-2R) and sCD8 antigens, and phenotypic changes of surface membrane antigens of the mononuclear cdls during treatment. We have evidence that the lymphocytes, especially T subsets, are stimulated on treatment with rhGM-CSF.
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HO ET AL rhGM-CSF for enhancement of peripheral hematopoietic progenitor cell yield. Twelve of the 14 patients had histologically confirmed high-or intermediate-grade non-Hodgkin's lymphoma (NHL), and two patients had Hodgkin's disease (HD) in advanced stages (111 and IV). All cases of NHL were of B-cell type. Kiel classification2' and the New Working Formulation" were used for defining subgroups of NHL. Clinical features of the patients are shown in Table 1 .
Chemotherapy regimen for patients with refractory NHL consisted of novantrone (NO) and high-dose Ara-C (AC) (NOAC).22 Refractory disease was defined as progressive disease under primary treatment (COP-BLAM/IMVP16)*' or relapse within 6 months of first remission. NO was administered at a dosage of 10 mg/m2/d on days -4 and -3 as rapid intravenous (IV) infusion (within 15 minutes). Ara-C was administered at 3 g/m2/12 h on Days -5 and -4 (four doses). Starting at day 0, rhGM-CSF was administered at a concentration of 250 pg/m2/24 h as a continuous infusion until the neutrophil count was more than 3.0/nL for 3 consecutive days.
Treatment was repeated between the fourth and sixth week. Response and toxicity were evaluated at the end of each course. Complete remission (CR) was defined as disappearance of all signs and symptoms of disease for at least 4 weeks. Bone marrow and peripheral blood had to be within normal range. Partial remission (PR) was defined as a reduction of measurable tumor parameters by at least 50% for more than 4 weeks. Progressive disease (PD) was defined as an increase of measurable tumor parameters by at least 25%. Response less than PR but not fulfilling the criteria for PD was classified as stable disease (SD). Six patients, four with NHL and two with HD, were treated with rhGM-CSF for enhancement of peripheral hematopoietic progenitor cell harvest and were in CR before study. rhGM-CSF was administered at a dosage of 200 to 250 pg/m2 daily as a continuous infusion. If the white blood cells (WBC) increased to more than lO.O/nL, harvesting of progenitor cells by means of a cell separator was started. The growth factor was administered continuously during the harvesting period of 8 to 10 days. However, the dosage would be reduced to 125 pg/m2 if the WBC exceeded 25.0/nL. If the WBC remained higher than 25.0/nL for 3 days, rhGM-CSF was withdrawn until a WBC count of <lO.O/nL was reached. Thus, the WBC were titrated within a range rhGM-CSF used in these studies was supplied by Behringwerke AG, Marburg, FRG, and Immunex, Inc, Seattle, WA.24 Human GM-CSF cellular DNA (cDNA) was isolated from a library constructed by using messenger RNA (mRNA) from the human T-cell line HUT-102 inserted and expressed in Escherichia coli. This agent was at least 95% pure, had a specific activity of 5 x io7 colony-forming units (CFU) per milligram of protein, and had no detectable endotoxin contamination as measured by the Limulus amebocyte assay. It was lyophilized and reconstituted with normal saline (0.9%) and 1% human albumin.
Before and during the course of the study, all patients were monitored by the daily recording of weight, blood pressure, pulse rate, oral temperature, physical examination, determination of complete WBC with differential and reticulocyte count, full biochemistry screens, and measurements of prothrombin time. Every other day mononuclear cells were isolated for phenotypic analysis and plasma samples were collected, aliquoted, and frozen for sIL-2R and sCD8 assays.
Preliminary experiments have shown that concentrations of sIL-2R and sCD8 were stable in frozen plasma at -7OOC for up to 18 months. Concentrations of IL-2R antigen in plasma were determined by a sandwich enzyme immunoassay (Cellfree IL2R Test Kit, T Cell Sciences, Cambridge, MA). An anti-IL-2R antibody (Anti-TAC equivalent) was first absorbed onto the wells of a polystyrene 96-well microtiter plate. Serial dilutions of each plasma specimen were added into each well and incubated at 37°C for 2 hours. After washing, a horseradish peroxidase conjugated anti-IL-2R monoclonal antibody (MoAb) directed against a second epitope was added. The wells were then washed and a substrate solution containing o-phenylenediamine (OPD) was pipetted into each well. The reaction was quenched with a I N solution of sulfuric acid and the absorbance was measured at 490 nm versus substrate blank. A standard curve was prepared using serial dilutions of a reference standard. Absorbance of the test wells was then compared with the standard curve and was converted to a numerical value. SIL-2R concentrations were expressed in U/mL, whereas 1,000 U is defined as the amount of released IL-2R present in 1.0 mL of a reference preparation provided by the supplier.
Similarly, levels of sCD8 were determined in the plasma samples by a sandwich enzyme immunoassay (Cellfree T8 Test Kit, T Cell Sciences). Plasma specimens were added into wells of a microtiter plate previously coated with the antibody anti-CDI. After incubation, the wells were washed and a horseradish peroxidase conjugated antibody directed against a second epitope on the CD8 molecule was added. Statistical analysis. Differences between groups of patients were analyzed using the Wilcoxon-Mann-Whitney-U-Test. Differences in blood counts in concentrations of sIL-2R or sCD8, and percentage change in lymphocyte subsets before and after treatment, were analyzed by the Wilcoxon-Pratt-Test.
RESULTS
Clinical characteristics of the patients are shown in Table  I . Patients who received rhGM-CSF to enhance hematopoietic progenitor cell harvest for autografting were younger than patients undergoing salvage chemotherapy plus rhGM-CSF. However, there was no significant difference in hemoglobin concentration and platelet or leukocyte counts between the two subgroups. None of the patients in this study had morphologic or phenotypic evidence of lymphoma cells in peripheral blood.
Changes in peripheral blood counts and in concentrations of sZL-2R and sCD8. Eight patients with relapsed or refractory N H L received rhGM-CSF, in addition to NOAC chemotherapy, and were monitored for different parameters (patients no. 1 to 8 in Table 1 ). Of these eight patients, three achieved C R (no. 1, 4, and 8 in Table l ) , two PR (no. 2 and 3), and two SD (no. 6 and 7) after the first course of treatment. Patient no. 5 had progressive disease despite chemotherapy.
After chemotherapy was started a t day -5, a drastic fall in leukocytes with a nadir of between 0.07 to 0.50/nL was observed within 6 to 10 days ( Fig 1A) . A recovery of neutrophils to >0.5/nL was found 7 to 11 days after initiation of rhGM-CSF administration (day 0). Courses of WBC are shown in Fig 1A. The median duration of rhGM-CSF therapy required to achieve a neutrophil count of There was an initial decline in slL-2R from day -5 t o day 0, but the concentration increased immediately after starting rhGM-CSF infusion (day 0). in contrast to the fall in WBCs from day 0 to day 6 (or in some cases to day 10). In three patients, the slL-2R concentrations on day 0 were not available, and the last values before day 0 were taken as baseline (dotted lines).
>3
.O/nL for 3 consecutive days was 14.5 days (range 14 to 17 days). By this time the WBCs were always higher than the pretreatment levels, but declined within 3 to 10 days to pretreatment range after discontinuation of rhGM-CSF. Changes in total and differential count in one of the patients (patient no. 6) during chemotherapy and rhGM-CSF treatment are shown in Fig 2. As shown in this case, there was also an increase in lymphocyte count a t the zenith of neutrophil elevation.
Effect of NOAC chemotherapy plus rhGM-CSF on the plasma levels of sIL-2R is shown in Fig 1B. Control persons (n = 17) had a median sIL-2R level of 310 U/mL, with a range from 155 to 650 U/mL in our laboratory. Patients with active disease (no. 1 to no. 8) had higher baseline concentrations of slL-2R, which declined initially on chemotherapy but rose rapidly on the first day of rhGM-CSF administration. Increase of sIL-2R preceded that of WBC by 7 to 11 days and returned to baseline levels 5 to 15 days after cessation of rhGM-CSF.
In six patients with C R treated with rhGM-CSF for enhancement of peripheral hematopoietic progenitor cell harvest, the WBC rose immediately within 1 to 2 days and reached a maximum at 5 to 14 days. Parallel to this rise, application of rhGM-CSF again caused an instant increase in sIL-2R concentrations. In Fig 3, the changes in WBC, lymphocytes, and sIL-2R in relationship to administration of rhGM-CSF are shown in one patient (no. 12). The WBC began to rise 36 hours after initiation of rhGM-CSF infusion and reached a maximum of 53.0/nL despite leukapheresis for progenitor cell harvest. Simultaneously, the concentration of sIL-2R increased from 620 U/nL to a maximum of 22,000 U/mL. After cessation of rhGM-CSF infusion, both sIL-2R and WBC returned to pretreatment levels within 10 days.
Maximum effect of rhGM-CSF on peripheral leukocyte counts in all 14 patients is summarized in Table 2 , in which the counts before therapy (including NOAC chemotherapy) and those at the zenith of WBC increase are given. Other than elevations in neutrophils, monocytes and eosinophils, there was also a significant increase in absolute lymphocyte count.
Maximum changes in sIL-2R and sCD8 upon administration of rhGM-CSF in the 14 patients are shown in Table 3 . In contrast to patients with active disease (no. 1 to 8), patients in C R (no. 9 to 14) had normal baseline levels of sIL-2R. Despite variations in baseline levels, a drastic increase in sIL-2R of 2.5 to 13.2-fold was observed in all 14 patients on rhGM-CSF treatment.
Median sCD8 concentration of control persons (n = 17) was 300 U/mL in our laboratory, with a range from 210 to 720 U/nL. Patients with active disease (no. 1 to 8) also had higher baseline concentrations of sCD8, whereas those in C R (no. 9 to 14) had normal levels. On chemotherapy, there was an initial drop in sCD8 concentrations but a gradual and [GM -CSF 2ooudm% 1 1 1 1 1 1 1 slL2R moderate increase was observed on administration of rhGM-CSF. Maximum increase in sCD8 of the 14 patients was statistically significant (P = .0128).
Two patients (no. 2 and 6 ) received a second course of NOAC chemotherapy, and patient no. 6 subsequently achieved PR whereas patient no. 2 remained in PR. Increases in absolute lymphocyte count, s I L -~R , and sCD8 concentrations during the second course were similar to the corresponding changes in the first treatment cycle (data not shown).
Days
Phenotypic studies of surface membrane antigens. In 10 of 14 patients, complete serial studies of the phenotypic surface antigens of the mononuclear cells could be performed (results are shown in Table 4 ). Patients in this study did not have evidence of circulating malignant cells by means of morphology and phenotypic studies of peripheral blood. After rhGM-CSF infusion, there was a significant increase in the percentages of CD25+(TAC+) and CD4-t cells in the lymphocyte fraction (P = .0020 and .0137, respec- elevations. The percentage of CD25 + cells also returned to pretreatment levels within 2 to 10 days after cessation of rhGM-CSF administration.
Changes during reconstitutions without exogenous rhCM-CSF. We studied concentrations of sIL-2R and sCD8 during hematopoietic reconstitution without exogenous rhGM-CSF in four patients undergoing different myelosuppressive therapy regimens. Two patients with refractory high-grade NHL received NOAC at the same dosage as patients no. 1 to 8, but without rhGM-CSF, and another patient with NHL underwent autologous bone marrow transplantation. Another patient received Ara-C (100 mg/ m2/12 h IV for 9 days) and daunorubicin (45 mg/m2/d IV for 3 days) treatment for acute myelogenous leukemia. Although a profound myelosuppression with subsequent recovery of WBC was found in all patients, no drastic change in sIL-2R levels was found. The median sIL-2R in these patients was 750 U/mL (range 410 to 1,300 U/mL) before treatment and 775 U/mL (range 470 to 2,100 U/mL) at the .O 128 Abbreviations: CT, rhGM-CSF administered after chemotherapy with NO and AC; PH, rhGM-CSF applied to enhance peripheral hematopoietic progenitor cell harvest. tively). An elevation in CD3 + cells after rhGM-CSF treatment was also found in 8 of 10 patients studied, but the overall increase was statistically not significant. No significant change in percentage of cells expressing CD19-t was found (Leu 12).
Controls
Analysis of monocyte fraction by FACscan in five patients showed that the monocytes were mostly negative for CD25 zenith of WBC recovery, with little variation during the observation period of 30 to 60 days. In contrast, concentrations of sCD8 decreased from a median of 420 U/mL (range 170 to 890 U/mL) to maximally 300 U/mL (range 100 to 450 U/mL) during WBC recovery phase. Thus, the courses in these patients illustrate that the hematopoietic regeneration itself is not associated with elevations in sIL-2R and sCD8 concentrations.
DISCUSSION
In 14 patients with malignant lymphoma, we have found that rhGM-CSF administration caused not only an expansion of peripheral neutrophils, monocytes, and eosinophils, but also an increase in absolute lymphocyte count. Parallel to this increase, a drastic rise in sIL-2R and a moderate elevation of sCD8 were observed.
In vivo effects of rhGM-CSF on peripheral blood counts in animals and patients have been reported in many In healthy primates, Donahue et a16 found that the absolute numbers of neutrophils, monocytes, and lymphocytes increased on continuous intravenous infusion of rhGM-CSF. However, in Rhesus monkeys after autologous bone marrow transplantation, treatment with rhGM-CSF did not result in an increase in lymphocyte^.^^.^^
In patients treated with rhGM-CSF for acquired immunodeficiency syndrome (AIDS), Groopman et a12' reported a threefold to fourfold increase in lymphocytes in several patients, although an overall dose-related change in absolute lymphocyte counts was not ~bserved.'~ Vadhan-Raj et a12* administered rhGM-CSF to eight patients with myelodysplastic syndromes and observed an increase in absolute number of lymphocytes from a mean baseline of 1,131 per cubic centimeter to the mean maximal response of 3,832. In a phase 1/11 trial on 11 patients with myelodysplastic syndrome, Ganser et a129 also showed an increase in the number of circulating lymphocytes that was directly correlated to the dosage of rhGM-CSF, but found no enhanced expression of IL-2R. No change in absolute lymphocyte counts was described in patients treated with rhGM-CSF after autologous bone marrow transplantation in the series of Brandt et a13' and Nemunaitis et aL3' Similarly, no effects on the lymphocytes were observed by Antin et a132 in patients treated for aplastic anemia and myelodysplastic syndrome, nor by Antman et all' in patients with sarcomas treated for chemotherapy-induced myelosuppression. In a phase Ib trial, Herrmann et a13' used rhGM-CSF as a therapy for 30 patients with different advanced tumors, and reported no change in lymphocyte counts and surface antigens. However, detailed results of the antigen studies in lymphocytes were not shown in the report.
Thus, a few of these studies seemed to support our present observation that the absolute lymphocyte counts increased after rhGM-CSF. However, the majority did not describe any significant change in lymphocytes. We have no definite explanation for this discrepancy yet. In most of these studies, emphasis has been focused mainly on changes in neutrophils and their precursors. In contrast, we have monitored different parameters related to lymphocyte activation in a prospective manner and a homogenous group of patients. The possibility cannot be excluded that this phenomenon is observed only in specific groups of patients, eg, patients with lymphoma.
The most drastic change in this study was a rise in sIL-2R that occurred within the first 36 hours after initiation of rhGM-CSF therapy. In patients treated with chemotherapy (NOAC), the increase was observed before the nadir of drug-induced pancytopenia and preceded the subsequent rise in WBC by 7 to 11 days. No significant increase in sIL-2R was found during hematologic reconstitution without exogenous rhGM-CSF after myeloablative therapy. In patients treated with rhGM-CSF alone for enhancement of peripheral hematopoietic progenitor cell harvest, the increase in sIL-2R levels paralleled that of WBC and was also found within the first 36 hours.
The soluble IL-2R is believed to be a truncated form of the 55-Kd chain of the membrane-associated r e c e p t~r '~ and is probably cleaved from the cells expressing IL-2R on their surface membrane.34 Clinical conditions associated with activation of lymphocytes and increase in IL-2R+ cells are characterized by high levels of s I L -~R .~' .~~ High levels of sIL-2R are also reported in patients with aggressive NHL.38.39 Although it is not known if the sIL-2R in these patients is derived from malignant cells or from activated normal lymphocytes, high levels seem to be related to advanced disease, great tumor burden, and poor p r o g n~s i s .~* .~~ Expression of IL-2R is not a specific property of activated T or B lympho~ytes.~'-~~ It has been shown that monocytes or macrophages could also be induced to express IL-2R after activation by interferon g a m~n a .~' .~~ As monocytes/macrophages have high levels of GM-CSF they might be activated by GM-CSF and induced to express IL-2R. Thus, these cells might also be a source of sIL-2R detected in our patients. However, Hancock et aI4j recently reported on a down-regulation of the expression of IL-2R on mononuclear phagocytes induced by rhGM-CSF. Our results from the analysis of the circulating mononuclear cells by means of flow cytometry have shown that there was an increase in percentage and intensity of CD25+ (TAC+) cells in the lymphocyte population after rhGM-CSF therapy, but much less so in the monocyte fraction. Two-color fluorescence studies of coexpression of CD25 and CD3 also showed that more than 90% of the CD25+ (TAC+) cells were found in the CD3+ subpopulation. Thus, the increase in CD25+ cells in peripheral blood seemed to be contributed mainly by activated T lymphocytes and not by the circulating monocytes.
As the concentrations of sIL-2R in our patients rose immediately on rhGM-CSF application, ie, before maximum cytoreductive effect of chemotherapy was reached, this antigen was probably released by resting cells not affected by cytotoxic drugs but stimulated by rhGM-CSF. Resting lymphocytes, monocytes, and tissue macrophages are possible candidates. Thus, the possibility cannot be excluded that the increase in sIL-2R in our patients is released by noncirculating macrophages/monocytes, which could also be stimulated by rhGM-CSF.44 Activation of T cells might then represent an epiphenomenon secondary to lymphokine secretion by activated macrophages/monocytes. As suggested by other investigators, the hematopoietic regulation network might be very complex in mammals, and the cell-to-cell interactions that mediate proliferation and differentiation are far from being defined.46 Whatever the cause of increase in s I L -~R , the significant increase in cells expressing CD25 within the CD3+ subpopulation, CD4+ cells, and absolute lymphocyte count on administration of rhGM-CSF all indicate that the lymphocytes are also activated directly or indirectly by rhGM-CSF.
Although no significant increase in the percentage of circulating CD8 + lymphocytes was observed on rhGM-CSF therapy, a significant increase in soluble CD8 concentration was found. Expression and release of CD8 seem to be specific properties of suppressor/cytotoxic T cell^.'^.'^ The advantage of determining the plasma levels of released antigens lies in that while activated cells secrete these antigens, some of these cells might never enter into circulation. Therefore, measurement of the released antigen might represent a more sensitive estimate of activation of cells expressing the corresponding antigen. Thus, the increase in sCD8 concentrations also indicates that some T subsets, eg, noncirculatory CD8 + cells are also stimulated by rhGM-CSF.
Originally believed to interact with cells of the myeloid lineage alone, rhGM-CSF had been shown to exert effects on leukemia cell lines derived from undifferentiated T-lymphocytic l e~k e m i a " . '~ and normal "IL-24riven" T ~e l l s . '~ In murine model, GM-CSF has been found to sustain the growth of a plasmocytoma cell line.47 These findings suggest that GM-CSF might also act on cells that have potential for lymphocyte differentiation. Our observations in vivo are further evidence that the effects of rhGM-CSF are not limited solely to myeloid lineages, and it may act directly or indirectly to support the proliferation of a t least some T-cell subsets in vivo.
In summary, our results provide evidence that effects of rhGM-CSF are not selective for cells of myeloid lineage, but may also activate T cells or T progenitors in vivo. This potential might be beneficial in augmenting the immune system, but the long-term impact is unknown. Due to their pleiotropic effects, the hematopoietic growth factors should be applied with caution in patients with malignant lymphoma, and prospective randomized trials are necessary to determine their clinical significance.
